Group items tagged

This Funding Opportunity Announcement (FOA) invites U01 applications for the continuation of the consortium to study Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) to conduct and complete ongoing studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes. The CPDPC is composed of several Clinical Centers (CC) and one Coordination and Data Management Center (CDMC) The Consortium since its establishment in Fall 2015 has conducted longitudinal clinical studies with comprehensive epidemiological and biological characterization of patients with CP (including those with Acute Recurrent Pancreatitis, ARP) to gain insight into the pathophysiology of chronic pancreatitis and its sequela: chronic pain, pancreatic insufficiency, T3cDM and the diabetes/pancreatic cancer association. The consortium has also undertaken studies on the development of pancreatic cancer in newly diagnosed diabetic patients. Applications for the Consortium Coordination and Data Management Center (CDMC) are being solicited via RFA-DK-19-504 "Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Coordination and Data Coordinating Center (CPDPC-CDMC) (U01 Clinical Trial Optional)". To effectively contribute to the ongoing CPDPC clinical studies, each CC applicant should include researchers and clinicians with multi-disciplinary expertise to match the objectives of the CPDPC (see https://cpdpc.mdanderson.org/clinicalstudies.html). Research CCs will be expected to share results freely within Consortium and to develop trans-Consortium collaborative projects that make use of the combined expertise and technological capabilities present in all of the CCs.

The overarching goal of the Breast Cancer and the Environment Research Program (BCERP) is to support integrated scientific research to enhance our understanding of environmental and genetic factors underlying breast cancer risk. This funding opportunity will support a Coordinating Center, which together with a group of individual transdisciplinary projects investigating the influence of environmental exposures during specific time windows on breast cancer risk, will form the BCERP Consortium. The BCERP Coordinating Center will provide intellectual leadership as well as logistic support for the BCERP Consortium. A primary role of the BCERP Coordinating Center will be to identify opportunities for cross-BCERP collaborations and extend the transdisciplinary activities of the BCERP Consortium. The Coordinating Center will also assist in disseminating BCERP research findings and facilitating an internal evaluation of the Consortium.

This Funding Opportunity Announcement (FOA) is a part of the Pediatric Preclinical Testing Consortium (PPTC) initiative. The PPTC will consist of in vivo and in vitro testing Research Programs (both supported under companion RFA-CA-14-018) and the PPTC Coordinating Center (supported under this FOA). The PPTC is designed to address key challenges associated with the development of new therapies for children with cancer by developing reliable preclinical testing data for pediatric drug candidates that can be used to inform new agent prioritization decisions. Effective prioritization is critical because of the large universe of drugs being developed for adult cancers, a number so large that no more than a small number can be studied in pediatric clinical trials. Identifying through preclinical testing those investigational agents most likely to have clinical activity for selected childhood cancers accelerates the pace at which treatments that are more effective than the current ones can be identified and incorporated into standard practice for children with cancer. The PPTC Research Programs, responsible for conducting the in vivo and in vitro testing of selected agents, will be focused on specific tumor types that are particularly relevant to pediatric oncology. The PPTC Coordinating Center, which is subject of this FOA, will be responsible for integrating the activities of the individual PPTC Research Programs to create a functional consortium for pediatric preclinical testing. Specifically, the PPTP-Coordinating Center will provide administrative coordination and infrastructure, data management and statistical support, as well as Consortium scientific coordination.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research projects addressing challenging cancer problems using systems biology approaches. In support of this goal, the National Cancer Institute (NCI) has initiated the Cancer Systems Biology Consortium (CSBC) through multiple FOAs. The CSBC network will consist of specialized U01 Research Projects (supported under this FOA), U54 CSBC Research Centers (supported under RFA-CA-15-014), and a U24 Coordinating Center (supported under RFA-CA-15-015).CSBC Research Projects should address a well-defined, discrete, and circumscribed research question in cancer incorporating quantitative experimentation, analysis, modeling and validation, which are the hallmarks of systems biology. As part of the CSBC, investigators from the Research Projects will have the opportunity to share resources and expertise across the Consortium and participate in Consortium activities and annual meetings.

This Funding Opportunity Announcement (FOA) invites applications to establish research teams of the Small-Cell Lung Cancer (SCLC) Consortium to conduct research whose overall goals are: 1) to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy. This FOA focuses on two of the five research priorities identified in the National Cancer Institute's 2014 Scientific Framework for Small Cell Lung Cancer (SCLC). Additional priorities of the Framework are stated in this FOA, as studies are expected to use or develop state-of-the-art research tools and omic profiles to identify therapeutic strategies that are relevant to human SCLC disease progression and resistance. The research supported by this FOA will be performed by individual research teams who are expected to collaborate with one another and with a central SCLC Coordinating Center. A third component of the SCLC Consortium focuses on prevention and early detection of SCLC.

This Funding Opportunity Announcement (FOA) is a part of an initiative designed to establish a Liver Cancer Consortium to advance translational research focused on early detection of liver cancer. The Consortium will consist of several Translational Research Centers (TRCs, to be supported by this U01 FOA) and a Data Management and Coordinating Center (DMCC, to be supported a companion U24 FOA, RFA-CA-17-028). The TRCs will conduct studies to improve the surveillance of liver cancer in members of high-risk populations, increase the fraction of liver cancer detected at an early stage, and better stratify patients at risk of developing liver cancer. Research to be conducted by TRCs must be based on appropriate range of biospecimens from cohorts that are focused on cirrhotic patients. A major collaborative effort of the TRCs will be the establishment of a well annotated repository of biospecimens. Biospecimens (blood, other body fluids, and, when feasible, liver tissue) may be already available and/or may be prospectively collected.

The Experimental Program to Stimulate Competitive Research (EPSCoR) is a program designed to fulfill the National Science Foundation's (NSF) mandate to promote scientific progress nationwide. The EPSCoR program is directed at jurisdictions that have historically received lesser amounts of NSF Research and Development (R&D) funding. Thirty-one jurisdictions including twenty-eight states, the Commonwealth of Puerto Rico, the U. S. Virgin Islands, and Guam currently are eligible to participate. Through this program, NSF establishes partnerships with government, higher education, and industry that are designed to effect lasting improvements in a state's or region's research infrastructure, R&D capacity and hence, its national R&D competitiveness.Research Infrastructure Improvement Program: Track-2 (RII Track-2) awards provide funds in the range of $1.5 to 2.0 million per year for up to 3 years to consortia of EPSCoR jurisdictions. The awards promote opportunities for collaborations among EPSCoR jurisdictions in all areas of science, engineering, and education supported by the National Science Foundation (NSF). RII Track-2 proposals must describe a clear, comprehensive, and integrated vision to drive discovery, and train a skilled workforce capable of solving science and engineering challenges of regional, thematic, and national relevance. Proposals should also include a strong rationale for the establishment of the consortium and clearly demonstrate that the consortium is well-positioned to produce results that cannot be obtained by any single partner working independently. The Science, Technology, Engineering, and Mathematics (STEM) research and education activities should broaden participation by different types of institutions, individuals, and sectors in the project.

The purpose of this FOA is to promote research on the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation E. Intensify research on the major drivers of childhood cancers: Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them. The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches.

The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches. Increased attention to this important but understudied field can help overcome existing barriers to progress and pave the way to novel therapeutic approaches with increased efficacy and fewer side effects than current options. The research teams comprising the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium will take a comprehensive approach to understanding the biology of fusion oncoproteins in childhood cancers and will use this information to inform strategies for therapeutic targeting.

This Funding Opportunity Announcement (FOA) is associated with the Beau Biden Cancer MoonshotSM Initiative that is intended to accelerate cancer research. The purpose of this FOA is to promote research on fusion oncoproteins in childhood cancers. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP): Recommendation E. Intensify research on the major drivers of childhood cancers: Improve our understanding of fusion oncoproteins in pediatric cancer and use new preclinical models to develop inhibitors that target them. The goal of this FOA is to establish a consortium of collaborating research teams to advance our understanding of the biology and mechanisms of action of fusion oncoproteins in pediatric cancers, and to apply this knowledge towards developing targeted therapeutic approaches. Increased attention to this important but understudied field can help overcome existing barriers to progress and pave the way to novel therapeutic approaches with increased efficacy and fewer side effects than current options. The research teams comprising the Fusion Oncoproteins in Childhood Cancers (FusOnC2) Consortium will take a comprehensive approach to understanding the biology of fusion oncoproteins in childhood cancers and will use this information to inform strategies for therapeutic targeting.

This Funding Opportunity Announcement (FOA) invites U01 applications for the establishment of a clinical consortium, composed of one Coordination and Data Management Center (CDMC) and up to 9 Clinical Centers (CC), to conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes.

This Funding Opportunity Announcement (FOA) invites U01 applications for the establishment of a clinical consortium, composed of one Coordination and Data Management Center (CDMC) and up to 9 Clinical Centers (CC), to conduct studies on chronic pancreatitis (CP) and factors that increase the risk of pancreatic cancer in patients (children and adults) with CP, pancreatogenic (type 3c) diabetes (T3cDM) and in patients with newly diagnosed diabetes.

This Funding Opportunity Announcement (FOA) is a part of the NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC). This reissuance of the CPTAC program leverages recent advancements in cancer proteomics and genomics and accelerates research in these areas by disseminating research resources for the scientific community. The program will support broad efforts focused on several cancer types to explore further the complexities of cancer proteomes and their connections to abnormalities in cancer genomes.

This Funding Opportunity Announcement (FOA) invites applications to establish research teams of the Small-Cell Lung Cancer (SCLC) Consortium to conduct research whose overall goals are: 1) to improve SCLC therapeutics, focusing on understanding how the molecular vulnerabilities of this cancer could be used to develop targeted agent combinations; and/or, 2) to gain a better understanding of the rapid development of clinical resistance to drug and radiation therapy.

The National Cancer Institute (NCI) will fund a new Cancer Systems Biology Consortium (CSBC) that includes U54 CSBC Research Centers, a Coordinating Center (to be supported under companion U24 RFA-CA-15-015) and other related research projects supported through the U01 mechanism. The CSBC initiative aims to address challenges of complexity in basic and translational cancer research through the use of experimental biology combined with in silico modeling, multi-dimensional data analysis, and systems engineering.

he NIH Research Education Cooperative Agreements Program (UE5) supports research education activities in the mission areas of the NIH.  The overarching goal of this National Cancer Institute (NCI) UE5  program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical cancer research needs. This UE5 funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative to establish the "NCI Awardee Skills Development Consortium (NASDC)."  The major objective of this initiative is to provide opportunities for current NCI grantees, especially those who are junior faculty (e.g., assistant professors, instructors, research scientists, or equivalent), to enhance their skills in areas that are critical for establishing and maintaining successful independent academic cancer research careers. To accomplish the stated overarching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development.  Such courses should contain innovative, state-of-the-art, evidence-based scientific and/or educational content that is essential to meet the academic career development needs of NCI-funded, junior faculty investigators.

This U24 funding opportunity announcement (FOA) is a part of the National Cancer Institute (NCI) initiative to establish the "NCI Awardee Skills Development Consortium (NASDC)."  The overarching goal of this initiative is to provide opportunities for current NCI grantees, especially those who are junior faculty (e.g., assistant professors, instructors, research scientists, or equivalent), to enhance their skills in areas that are critical for establishing and maintaining successful independent academic cancer research careers. This U24 FOA solicits applications for a Coordinating Center to address the NASDC logistics and evaluation needs in serving the NASDC Research Education Short Courses that will be supported by a companion UE5 FOA (RFA-CA-19-010). 

Research progress in the treatment for diseases of the exocrine pancreas [chronic pancreatitis (CP), pancreatogenic diabetes mellitus, and pancreatic cancer] has been hampered by the disorders' heterogeneity, the limitations of previous small cross-sectional studies, the inability to safely obtain pancreatic tissue for discovery, and the lack of structured epidemiology tools, genetic testing, and biomarker development and validation. Mechanism-based research of these diseases has suffered from the lack of systematically collected clinical measures in longitudinal cohort studies linked with biospecimens. Given the increasing incidence and prevalence of CP and its association to the development of pancreatic cancer, its complications, high mortality rate, and associated health care cost, the National Institute for Diabetes and Digestive and Kidney Diseases and the National Cancer Institute established in 2015 the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) Consortium as multidisciplinary teams composed of members from the Clinical Centers and Coordination and Data Management Center to undertake a comprehensive clinical, epidemiological, and biological characterization of patients with CP (including adults and children with recurrent acute pancreatitis) to develop treatments and gain insight into the pathophysiology of CP and its sequela: chronic pain, pancreatic exocrine and endocrine insufficiency, T3cDM, and the diabetes/pancreatic cancer association. Another objective was to undertake studies on the development of pancreatic cancer in newly diagnosed diabetic patients

Through this limited competition Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) solicits a single application for the continuation of the AIDS and Cancer Specimen Resource (ACSR). The eligible applicant institutions (which are the two current NCI-supported ACSR lead institutions) are expected to maintain the cooperative group structure and the activities of the ACSR. The primary objective of the ACSR will be to acquire, store, and equitably distribute tumor tissues, biological fluids, and associated demographic data from patients with human immunodeficiency virus (HIV)-associated malignancies. In addition to serving acquired immunodeficiency syndrome (AIDS) and cancer researchers at large, the ACSR will specifically provide biorepository functions for another NCI supported initiative, the AIDS Malignancy Consortium (AMC). The AMC performs clinical trials research in the treatment and prevention of HIV-associated malignancies in the United States and Sub-Saharan Africa. As the AMC is currently expanding its agenda to include Latin America, it is expected that the ACSR will collaborate with the AMC to develop regional biorepository support for AMC activities in Latin American countries. The continuing ACSR must have appropriate strategies and capabilities to address several high priority areas of specimen acquisition including specific types of cancer (AIDS-defining as well as non-AIDS defining), types of biospecimens and accompanying clinical data, and biospecimens from geographic areas of interest.

The purpose of this FOA is to promote the creation of developing research centers that can build capacity to study high priority areas of cancer control implementation science, build implementation laboratories, improve the state of measurement and methods, and improve the adoption, implementation, and sustainment of evidence-based cancer control interventions. Specifically, this FOA targets the following areas designated as scientific priorities by the Blue Ribbon Panel (BRP): Prevention and Screening: Implementation of Evidence-based Approaches; Symptom Management, Prevention and Screening: High-Risk Cancers and other cross-cutting Moonshot priorities. The Implementation Science Centers in Cancer Control (ISCCC) Program will support the rapid development, testing and refinement of innovative approaches to implementing a range of evidence-based cancer control interventions, establish implementation laboratories from existing clinical and community sites providing services across the cancer control continuum, advance methods in studying implementation, develop and validate reliable measures of key implementation science constructs, and together form a large consortium of implementation scientists across this and other Moonshot initiatives. The ISCCC Program will support P50 Developing Centers (under this FOA) and P50 Advanced Centers (companion RFA-CA-19-006).